Acute ST Elevation Myocardial Infarction Clinical Trial
Official title:
A Randomised Controlled Trial to Compare Unfractionated Heparin Versus Bivalirudin in the Treatment of Patients With a Clinical Diagnosis of ST-Segment Elevation Myocardial Infarction Events - For Planned Management With Primary PCI
The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial. Interventional procedures will be performed to reflect current and evolving standards, including predominant radial access. All patients will be treated with routine oral anti-platelet therapy pre-procedure. GP IIb/IIIa inhibitors will be reserved for 'bail out' treatment only.
HEAT-PPCI is a single-centre prospective, dual-arm, open-label, randomised controlled trial
comparing two antithrombotic agents in patients undergoing PPCI. All patients presenting to
the PPCI service at Liverpool Heart and Chest Hospital will be assessed for trial
eligibility. The patients will be allocated by randomisation in equal proportions to the two
treatment groups receiving UFH (70 units/kg prior to the procedure) or bivalirudin (bolus of
0.75 mg/kg prior to the start of the intervention, followed by an infusion of 1.75 mg/kg per
hour for the duration of the procedure).
Pre-Specified Subgroup Analyses
- Subgroup analyses looking at the impact of access site comparing radial versus femoral
route
- Assessment of the outcomes in diabetic patients receiving oral hypoglycaemic or insulin
therapy versus all other patients
- Comparing the outcomes in patients < or ≥ 75 years of age
- Type of p2y12 receptor inhibiting antiplatelet agent (Examples: clopidogrel, prasugrel,
ticagrelor)
- Patients with impaired LV function versus normal LV function
- Patients managed with actual or attempted primary PCI versus no immediate PCI procedure
attempted
PLATELET FUNCTION SUBSTUDY A substudy will be performed to assess indices of coagulation and
platelet function studies comparing the impact of heparin or bivalirudin therapy on
coagulation status at the end of the PPCI procedure. This study will be performed on all
patients treated between the hours of 0800 and 1600, Monday to Friday. A single blood sample
taken at the time of general blood sampling for routine clinical screening will be analysed.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00378352 -
REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
|
Phase 2 | |
Completed |
NCT02835534 -
The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
|
Phase 4 | |
Completed |
NCT01388504 -
Nitrites in Acute Myocardial Infarction
|
Phase 2/Phase 3 | |
Completed |
NCT01878487 -
Assessment of Lumen Expansion After Thrombus Extraction in Primary Percutaneous Coronary Intervention
|
N/A | |
Recruiting |
NCT00284323 -
Salvage: Postconditioning With Adenosine for STEMI
|
Phase 2 |